Literature DB >> 15050952

Medulloblastoma: signalling a change in treatment.

Richard J Gilbertson1.   

Abstract

Medulloblastoma is the most common malignant brain tumour that occurs during childhood. Multimodality treatment regimens have substantially improved survival in this disease; however, the tumour is incurable in about a third of patients with medulloblastoma, and current treatment has a detrimental effect on long-term survivors. Drugs that target cell-signalling pathways provide an alternative to conventional cytotoxic approaches to treatment of cancer. Several pathways have been implicated in medulloblastoma formation, and knowledge of these is now being used to develop new ways of treating children with medulloblastoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050952     DOI: 10.1016/S1470-2045(04)01424-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  104 in total

1.  mGlu Receptors and Cancerous Growth.

Authors:  Jessica Teh; Suzie Chen
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2011-10-25

Review 2.  Medulloblastoma-biology and microenvironment: a review.

Authors:  Tiara Byrd; Robert G Grossman; Nabil Ahmed
Journal:  Pediatr Hematol Oncol       Date:  2012-06-28       Impact factor: 1.969

3.  Inhibition of tumor cell migration and invasion through knockdown of Rac1 expression in medulloblastoma cells.

Authors:  Baodong Chen; Yongzhong Gao; Taipeng Jiang; Jianjun Ding; Yanjun Zeng; Ruxiang Xu; Xiaodan Jiang
Journal:  Cell Mol Neurobiol       Date:  2010-11-13       Impact factor: 5.046

4.  Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma.

Authors:  Zhong Deng; Zhuo Wang; Chaomei Xiang; Aliah Molczan; Valérie Baubet; Jose Conejo-Garcia; Xiaowei Xu; Paul M Lieberman; Nadia Dahmane
Journal:  J Cell Sci       Date:  2012-05-28       Impact factor: 5.285

5.  Analysis of microsatellite instability in medulloblastoma.

Authors:  Marta Viana-Pereira; Inês Almeida; Sónia Sousa; Bethânia Mahler-Araújo; Raquel Seruca; José Pimentel; Rui Manuel Reis
Journal:  Neuro Oncol       Date:  2009-01-29       Impact factor: 12.300

6.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

7.  Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.

Authors:  Mariane Jaeger; Carolina Nör; Caroline Brunetto de Farias; Ana Lucia Abujamra; Gilberto Schwartsmann; Algemir Lunardi Brunetto; Rafael Roesler
Journal:  Childs Nerv Syst       Date:  2013-10-03       Impact factor: 1.475

Review 8.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

9.  p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.

Authors:  Raya Saab; Carlos Rodriguez-Galindo; Kelly Matmati; Jerold E Rehg; Shannon H Baumer; Joseph D Khoury; Catherine Billups; Geoffrey Neale; Kathleen J Helton; Stephen X Skapek
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

10.  p53 Regulates LIF expression in human medulloblastoma cells.

Authors:  Euan W Baxter; Jo Milner
Journal:  J Neurooncol       Date:  2009-11-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.